Eletriptan

CLINICAL USE

Acute relief of migraine

DOSE IN NORMAL RENAL FUNCTION

40–80 mg repeated after 2 hours if migraine recurs (do not take 2nd dose for the same attack)Maximum 80 mg in 24 hours

PHARMACOKINETICS

Molecular weight :463.4 (as hydrobromide)

%Protein binding :85

%Excreted unchanged in urine : 9

Volume of distribution (L/kg) :2–2.5

half-life – normal/ESRD (hrs) :4/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

30–50 20 mg; maximum daily dose 40 mg10–30 20 mg; maximum daily dose 40 mg, use with caution

<10 : 20 mg; maximum daily dose 40 mg, use with caution

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unknown dialysability. Dose as in GFR <10 mL/min

HD :Unknown dialysability. Dose as in GFR <10 mL/min

HDF/high flux :Unknown dialysability. Dose as in GFR <10 mL/min

CAV/VVHD :Unknown dialysability. Dose as in GFR=10–30 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antibacterials: concentration increased by clarithromycin and erythromycin – avoid concomitant use

Antidepressants: possibly increased serotonergic effects with duloxetine; increased serotonergic effects with St John’s wort – avoid concomitant use

Antifungals: concentration increased by itraconazole and ketoconazole – avoid concomitant use

Antivirals: concentration increased by indinavir, nelfinavir and ritonavir – avoid concomitant use

Ergot alkaloids: increased risk of vasospasm

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Non-renal clearance accounts for about 90% of the total clearanceManufacturer advises to avoid in severe renal impairment due to enhanced hypertensive effect.

Tags: post-by-auto-php